Cargando…
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467041/ https://www.ncbi.nlm.nih.gov/pubmed/28210002 http://dx.doi.org/10.1038/leu.2017.58 |
| _version_ | 1783243201278115840 |
|---|---|
| author | Martinez-Lopez, J Sanchez-Vega, B Barrio, S Cuenca, I Ruiz-Heredia, Y Alonso, R Rapado, I Marin, C Cedena, M-T Paiva, B Puig, N Mateos, M-V Ayala, R Hernández, M-T Jimenez, C Rosiñol, L Martínez, R Teruel, A-I Gutiérrez, N Martin-Ramos, M-L Oriol, A Bargay, J Bladé, J San-Miguel, J Garcia-Sanz, R Lahuerta, J-J |
| author_facet | Martinez-Lopez, J Sanchez-Vega, B Barrio, S Cuenca, I Ruiz-Heredia, Y Alonso, R Rapado, I Marin, C Cedena, M-T Paiva, B Puig, N Mateos, M-V Ayala, R Hernández, M-T Jimenez, C Rosiñol, L Martínez, R Teruel, A-I Gutiérrez, N Martin-Ramos, M-L Oriol, A Bargay, J Bladé, J San-Miguel, J Garcia-Sanz, R Lahuerta, J-J |
| author_sort | Martinez-Lopez, J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5467041 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54670412017-06-22 Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma Martinez-Lopez, J Sanchez-Vega, B Barrio, S Cuenca, I Ruiz-Heredia, Y Alonso, R Rapado, I Marin, C Cedena, M-T Paiva, B Puig, N Mateos, M-V Ayala, R Hernández, M-T Jimenez, C Rosiñol, L Martínez, R Teruel, A-I Gutiérrez, N Martin-Ramos, M-L Oriol, A Bargay, J Bladé, J San-Miguel, J Garcia-Sanz, R Lahuerta, J-J Leukemia Letter to the Editor Nature Publishing Group 2017-06 2017-03-10 /pmc/articles/PMC5467041/ /pubmed/28210002 http://dx.doi.org/10.1038/leu.2017.58 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spellingShingle | Letter to the Editor Martinez-Lopez, J Sanchez-Vega, B Barrio, S Cuenca, I Ruiz-Heredia, Y Alonso, R Rapado, I Marin, C Cedena, M-T Paiva, B Puig, N Mateos, M-V Ayala, R Hernández, M-T Jimenez, C Rosiñol, L Martínez, R Teruel, A-I Gutiérrez, N Martin-Ramos, M-L Oriol, A Bargay, J Bladé, J San-Miguel, J Garcia-Sanz, R Lahuerta, J-J Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title_full | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title_fullStr | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title_full_unstemmed | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title_short | Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
| title_sort | analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase ii trial for multiple myeloma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467041/ https://www.ncbi.nlm.nih.gov/pubmed/28210002 http://dx.doi.org/10.1038/leu.2017.58 |
| work_keys_str_mv | AT martinezlopezj analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT sanchezvegab analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT barrios analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT cuencai analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT ruizherediay analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT alonsor analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT rapadoi analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT marinc analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT cedenamt analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT paivab analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT puign analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT mateosmv analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT ayalar analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT hernandezmt analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT jimenezc analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT rosinoll analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT martinezr analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT teruelai analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT gutierrezn analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT martinramosml analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT oriola analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT bargayj analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT bladej analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT sanmiguelj analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT garciasanzr analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma AT lahuertajj analyticalandclinicalvalidationofanovelinhousedeepsequencingmethodforminimalresidualdiseasemonitoringinaphaseiitrialformultiplemyeloma |